Companies Collaborate in Their Aim to Accelerate Accurate Diagnosis
of Cancer for Patients in China
Company Website:
http://www.agilent.com/go/news
SANTA CLARA, Calif. & GUANGZHOU, China -- (Business Wire)
Agilent Technologies Inc. (NYSE:A) and Burning Rock today announced they
have signed an agreement under which Burning Rock will develop cancer
diagnostics in China based on the Agilent SureSelect target enrichment
system.
Agilent is the leading provider of target enrichment for next-generation
DNA sequencing. Target enrichment saves researchers time and resources
by enabling them to focus on regions of interest rather than looking at
the entire genome. Burning Rock is a fast-growing company focused on
developing cancer diagnostics based on DNA sequencing.
“As the leader in molecular cancer diagnosis in China, Burning Rock is
very pleased to partner with Agilent, a global leader in diagnostics and
genomics,” said Yusheng Han, the founder and chief executive officer of
Burning Rock. “Collaboration between our two companies will provide
additional high-quality molecular diagnostic solutions based on
next-generation sequencing, including non-invasive testing, relapse
monitoring, early-stage diagnosis and cancer susceptibility.”
Fast and accurate cancer diagnoses are becoming increasingly important
in China, with its extensive population and growing focus on advancing
human health.
“We are excited to partner with Burning Rock to accelerate accurate
diagnosis of cancer for patients in China,” said Jacob Thaysen,
president of Agilent’s Diagnostics and Genomics Group. “We believe that
target enrichment and next-generation sequencing have a vital role to
play in personalizing medicine and ultimately delivering treatments
tailored to the individual. This is especially so for complex diseases
such as cancer.”
Burning Rock plans to register its molecular diagnostic kit with the
China Food and Drug Administration. The company believes the kit could
become the first CFDA-approved capture sequencing-based cancer
diagnostic assay in the Chinese market.
About Burning Rock
Burning Rock is headquartered in Beijing, China, and is a diagnostics
company committed to the field of molecular testing to improve oncology
patients’ individualized treatment guidance. It offers research and
commercialized clinical laboratory services mainly through
bioinformatics on next-generation sequencing platforms. Burning Rock has
a state-of-the-art molecular and pathological examination platform and
has developed a series of testing solutions. To learn more, visit www.brbiotech.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences,
diagnostics and applied chemical markets, is the premier laboratory
partner for a better world. Agilent works with customers in more than
100 countries, providing instruments, software, services and consumables
for the entire laboratory workflow. The company generated revenue of
$4.04 billion in fiscal 2015 and employs about 12,000 people worldwide.
Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005037/en/
Contacts:
Agilent Technologies, Inc.
Victoria Wadsworth-Hansen, +1
408-553-2005
+45 2933 6980
victoria.wadsworth-hansen@agilent.com
or
Burning
Rock
Pan Yingying, +86 21 6029 3721
yingying.pan@brbiotech.com
Source: Agilent Technologies Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.